Effects of Rifaximin on Bloating, Gut Microbiome, Metabolome, and Intestinal Gas in Patients With Irritable Bowel Syndrome With Constipation or Functional Abdominal Bloating Defined by Rome V Criteria: A Randomized, Double-Blind, Placebo-Controlled Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07522255

Title field or adapter rule

{'original_value': 'Effects of Rifaximin on Bloating, Gut Microbiome, Metabolome, and Intestinal Gas in Patients With Irritable Bowel Syndrome With Constipation or Functional Abdominal Bloating Defined by Rome V Criteria: A Randomized, Double-Blind, Placebo-Controlled Trial', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:34.586998+00:00

Published At

2026-10-27T00:00:00+00:00

Record Updated At

2026-10-27

Source Retrieved At

2026-10-31T22:18:47.153665+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Bloating", "Rifaximin", "Functional Bowel Disorder", "Irritable Bowel Syndrome", "Constipation", "Microbiota", "Metabolomic Profile"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-27", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07522255"

protocolSection.identificationModule.officialTitle

"Effects of Rifaximin on Bloating, Gut Microbiome, Metabolome, and Intestinal Gas in Patients With Irritable Bowel Syndrome With Constipation or Functional Abdominal Bloating Defined by Rome V Criteria: A Randomized, Double-Blind, Placebo-Controlled Trial"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Bloating (protocolSection.conditionsModule.conditions)
• Rifaximin (protocolSection.conditionsModule.conditions)
• Functional Bowel Disorder (protocolSection.conditionsModule.conditions)
• Irritable Bowel Syndrome (protocolSection.conditionsModule.conditions)
• Constipation (protocolSection.conditionsModule.conditions)
• Microbiota (protocolSection.conditionsModule.conditions)
• Metabolomic Profile (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Rifaximin'], 'description': 'Participants randomized to this arm receive rifaximin 550 mg orally three times daily for 2 weeks. Allocation is randomized and double-blinded.', 'name': 'Rifaximin (drug)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Placebo'], 'description': 'Matching placebo administered orally three times daily for 14 days.', 'name': 'Placebo', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Rifaximin (drug) (protocolSection.armsInterventionsModule.interventions[].name)
• Placebo (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.